中国经济网北京7月1日讯(记者周宇宁)2025年服贸会"高管谈服贸"系列活动近日走进位于北京的阿斯利康中国区域总部，该公司今年将第五次参加中国国际 服务贸易交易会，全面展示其最新成果。 "阿斯利康积极响应乡村振兴战略，推动优质医疗资源下沉。"黄彬介绍，凭借广泛的医疗资源覆盖，阿斯利康深入400个城市及2800个县区，助力早筛早 诊、精准诊断与治疗工作的开展。与此同时，通过开展义诊等公益活动，阿斯利康积极助力填补乡村医疗资源的缺口，让偏远地区的患者也能享受到优质医 疗服务。同时还通过人才培养、技术援助等方式，支持提升乡村基层医疗人员的专业水平，帮助建立更完善的乡村医疗服务体系。 黄彬表示，未来阿斯利康将继续秉持企业社会责任理念，不断探索创新，为中国乃至全球的医疗健康事业发展贡献更多力量，与社会各界携手共创更加美好 的未来。 阿斯利康(中国)副总裁黄彬介绍，阿斯利康深耕中国三十多年来，始终将创新视为推动医疗进步的核心动力。从2024年将位于上海的研发中心升级为全球第 五大战略研发中心，再到2025年宣布投资25亿美元，在北京建立第六个全球战略研发中心，不断扩大的研发布局彰显着其深耕中国的决心。目前，阿斯利康 中国 ...

Core Viewpoint - The company, Zhonghong Medical, is actively engaging in multi-dimensional exploration in medical innovation, aiming to enhance life-saving capabilities and improve diagnostic and treatment levels in the rapidly evolving medical technology landscape [1] Group 1: Innovation and Business Development - In recent years, Zhonghong Medical has made significant strides in its innovation incubation business, establishing three major divisions in 2022 to enhance core competitiveness and market influence [2] - At the 2024 China International Medical Equipment Fair (CMEF), Zhonghong Medical showcased two new brands under its innovation incubation initiative: "Zhonghong Maid" focusing on infusion management and "Zhonghong Weimai" offering advanced temperature management solutions [2] - The collaboration with Weimai Intelligent Technology for "Zhonghong Weimai" aims to provide digital, real-time, intelligent, and automated perioperative temperature management solutions, significantly improving medical outcomes and service quality [2] Group 2: Strategic Partnerships - Zhonghong Medical has entered into a distribution agreement with Jincheng Rui Medical, allowing it to distribute various medical products, including disposable non-invasive EEG electrodes and temperature sensors, thereby expanding its product pipeline [2][3] - The partnership with Jincheng Rui Medical is expected to enhance Zhonghong Medical's market share and influence in relevant fields while leveraging its extensive sales network to improve product reach [3] Group 3: Future Outlook - Looking ahead, Zhonghong Medical is poised to continue launching new products and exploring new markets through sustained innovation investment and diversified collaboration models [4] - The company aims to solidify its position in the medical device industry and progress towards becoming a global leader in comprehensive medical health products and services [4]

据丰台区医药大健康专班执行召集人毛山宏介绍，自去年5月首届智能医工大会举办以来，丰台区组建 了医药大健康产业专班，200多位顶尖专家组成专家委员会。同时，建立医药大健康创新服务中心，引 入天坛国际脑健康中心、西门子医疗首个开放式医工转化平台等一批企业和机构，已推动一批创新产品 实现临床应用。 以脑血管介入术为例，传统造影术需要医护人员身着铅衣、铅围脖才能进行，有了手术机器人，医生在 手术间外的操作台前，通过操作手柄控制机械臂即可完成手术，解决了血管介入术医生受辐射损伤的临 床痛点。该机器人取得我国首张三类医疗器械注册证，已在国内多家三甲医院完成临床验证。 在无创血糖仪展台前，糖尿病患者郑女士体验了无创血糖检测。与传统的指尖采血检测相比，该检测无 痛感，且准确性更高。据介绍，无创血糖仪采用代谢热整合法技术，通过多传感器集成实现血糖无创检 测，检测结果与静脉血一致性达94.5%。 新京报讯（记者姜慧梓）手术机器人、无创血糖仪、AI热疗仪、手术导航机器人……6月26日，一批医 疗领域创新成果在天坛智能医工产业园亮相。 当天，2025中关村论坛系列活动——"智能医工创新发展论坛"暨丰台区第二届智能医工产业创新发展大 ...

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. CONTENTS | Advancing Towards High-Quality | Safeguarding Lives and | Development | Empowering People | | | | | --- | --- | --- | --- | --- | --- | --- | | Management | 13 | Enhancing Corporate Governance | 61 | Human Capital Development | Development: Empowering | Friendliness: Creating a | | Life Through Technology | Shared Green Future | Jiangsu Yuyue Medical Equipment & | Supply Co., | | | | | Ltd. | 2024 Sustainability Report | | | | | | | Message from ...

Johnson & Johnson (JNJ) FY 2025 Conference May 28, 2025 09:00 AM ET Speaker0 Alright. Thank you, everybody. Thanks, guys. I'm Lee Hambrite, US med tech analyst at Bernstein, and we are thrilled to host Johnson and Johnson. We have chairman and CEO, Joaquin Guato, and CFO, Joe Wall. Guys, for being here. Speaker1 Thank you. Thanks for having us. Speaker0 So we're scheduled for a fifty minute fireside chat. Just a reminder that investors can submit questions at any time through Pigeonhole, and we'll try to wo ...

Assertio Holdings (ASRT) Conference Summary Company Overview - Assertio Holdings is a specialty pharmaceuticals company with a market cap of approximately $70 million and shares trading at around 70¢ [2][4] - The company is focused on long-term growth and has a leadership team with extensive commercial experience in various therapeutic areas [5][6] Core Assets and Financial Performance - Assertio's core assets include Rovidone and SYMPAZAN, with Rovidone being a novel long-acting G-CSF approved in the last twenty years, targeting a market worth about $1 billion [8][9] - The company reported net sales of $26 million for the first quarter and maintains a positive adjusted EBITDA with a cash balance of nearly $90 million [9] - The financial outlook for the year includes projected net sales of $108 to $123 million and non-GAAP EBITDA of $10 to $20 million [10] Transformation and Growth Strategy - The company is in a transformation phase, simplifying its corporate structure and optimizing its asset portfolio, focusing on growth assets like Rovidone and SYMPAZAN [12][15] - Assertio aims to reduce legal exposure, which will allow for reinvestment into the business and positively impact EBITDA [13][14] - Business development is seen as a key enabler for future growth, with a focus on oncology, neurology, and rare diseases [14] Product Insights - Rovidone contributes over half of the total net sales and is expected to grow modestly this year, with plans to expand into the commercial segment by 2026 [19][21] - SYMPAZAN, an oral film formulation for Lennox Gastaut syndrome, is projected to grow to $13 million this year and has the potential to reach $25 million in the coming years [28] Competitive Landscape - The market for white blood cell stimulants is competitive, with Rovidone competing against biosimilars like Neulasta. Assertio is focused on managing average selling prices (ASP) smartly to sustain growth [23][24] Legal and Operational Improvements - Assertio has successfully reduced its litigation overhead, particularly related to opioid litigation, which has allowed for a cleaner balance sheet and operational focus [36][38] - The company has divested certain assets to streamline operations and eliminate legal distractions [38] Future Outlook - The CEO expressed optimism about the company's trajectory, aiming for significant growth and improved operational efficiency over the next year [41][42] - Assertio is positioned to explore mergers and acquisitions to enhance its portfolio, supported by a strong balance sheet with $40 million in convertible debt due in 2027 [34][35] Key Takeaways - Assertio is undergoing a transformation aimed at growth, with a focus on optimizing its asset portfolio and reducing legal distractions [12][15] - The company has a solid financial outlook and is strategically positioned to capitalize on growth opportunities in specialty pharmaceuticals [10][14] - Assertio's leadership is optimistic about future performance, with plans to enhance product offerings and expand market presence [41][42]

19五月2025 | 下午5:56（美国东部夏令时间） Moderator: Sarah Herr – US Research Merchandising n 会议要点： Kroger Co. (KR): 全球日用品论坛2025 — 核心要点 通用磨坊公司（GIS）：2025年全球粮油论坛——关键要点 n 康加品牌公司（CAG）：2025年全球主食论坛——关键要点 研究报告解密：2025年全球文具论坛要点 在这个播客中，我们收听Bonnie Herzog和Leah Jordan加入Sarah Herr，回顾我 们在纽约于5月13日举办的全球消费必需品会议的亮点。 th ，以及在夏季及以后 影响该部门股票的主要争论。 我们鼓励您访问我们的会议网站，"此处"获取议程、演示文稿和要点笔记 。 Speakers: 邦妮·赫佐格——饮料、HPC、烟草及便利店分析师 n Leah Jordan – 包装食品与食品零售分析师 n Vita Coco Co. Inc. (COCO): 全球主食论坛2025 — 核心要点 Church & Dwight Co. (CHD): 全球必需品论坛2025 — 来自关键观点的摘录 n ...

灵活精准操作：蛇形臂具备360°全维度弯转能力，可绕过锁骨、气管、血管等障碍，精准分离喉返神经 后方淋巴结，避免"筷子效应"，术中出血量控制在10ml以内。 甲状腺外科手术经历了开放手术、腔镜手术、多孔机器人手术的发展过程。相比较开放手术而言，腔镜 手术、多孔机器人手术达到了显著提升精细化操作和隐藏颈部手术疤痕的目的，但也存在需创建多个通 道置入器械或扩大单一通道切口的问题，否则会增加器械间相互的"筷子效应"。同时因为锁骨的阻挡和 直臂器械操作的限制，有时会非常影响手术部位的到达和手术操作的顺利实施。蛇形臂单孔机器人为解 决上述弊端提供了可能性。 李勤裕主任作为国内甲状腺微创手术领域的权威专家，已完成数千例复杂甲状腺手术和甲状腺微创手 术。在此次手术中，团队创新性应用国产术锐蛇形臂单孔机器人，独创的蛇形手术臂技术，在狭窄解剖 空间中展现了卓越的灵活性与精准度，减少了通道内组织结构对器械操作的影响，精准地实施了甲状腺 腺叶切除和淋巴结清扫。 与传统直杆腔镜相比，术锐蛇形臂单孔手术机器人在腋下入路手术中具有以下显著优势： 超微创设计：仅需直径2.5厘米的单一腋下切口，切口隐蔽于腋窝褶皱，术后几乎无痕，完美满足患者 ...

Core Insights - Jeito Capital has promoted Mehdi Ainouche to Partner and Julien Elric to Senior Principal, reflecting the firm's growth and commitment to internal talent development [1][6] Group 1: Promotions and Roles - Mehdi Ainouche joined Jeito in 2020 and has played a crucial role in the investment cycle, particularly with the successful sale of EyeBio to Merck & Co for up to $3 billion [2][3] - Julien Elric joined Jeito in 2021 and has been instrumental in financing and clinical development strategies, notably contributing to the investment and exit of HI-Bio acquired by Biogen Inc. for up to $1.8 billion [4][5] Group 2: Company Overview - Jeito Capital is a leading global Private Equity fund focused on biopharma, dedicated to financing and accelerating medical innovations with a patient benefit-driven approach [7] - The firm has built a diversified portfolio of clinical biopharmas addressing high unmet medical needs, with a presence in Europe and the United States [7]

Company Overview - Jeito Capital is a leading independent Private Equity fund focused on biopharma, dedicated to financing and accelerating the development of groundbreaking medical innovations [7] - The firm has a diversified portfolio of clinical biopharmas that address high unmet medical needs, with a strong presence in Europe and the United States [7] Promotions and Team Development - Mehdi Ainouche has been promoted to Partner, and Julien Elric to Senior Principal, reflecting Jeito's commitment to talent development and internal career progression [1][6] - Mehdi joined Jeito in 2020 and has played a crucial role in the investment cycle, particularly noted for the successful sale of EyeBio to Merck & Co for up to $3 billion [2] - Julien joined Jeito in 2021 and has been instrumental in financing and clinical development strategies, contributing to the investment and exit of HI-Bio™ acquired by Biogen Inc. for up to $1.8 billion [4] Leadership Insights - Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, expressed delight in the promotions, highlighting the significant contributions of Mehdi and Julien to the firm's mission of unlocking the potential of portfolio companies [6]